Achievement of pH-independence of poorly-soluble, ionizable loratadine by inclusion complex formation with dimethyl-β-cyclodextrin

Journal of Inclusion Phenomena and Macrocyclic Chemistry

Volumn 64, Issue 3-4, 2009, Pages 249-254

  Nacsa, A ^a   Berkesi, O ^a   Szabo Revesz P ^a   Aigner, Z ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Co crystal; DIMEB; FT IR; Loratadine; PH independent solubility; Thermal analysis

Indexed keywords

EID: 70349705738     PISSN: 09230750     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10847-009-9558-1     Document Type: Article

References (25)

1. Merisko-Liversidge, E., Liversidge, G.G., Cooper, E.R.: Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18, 113-120 (2003). doi:10.1016/S0928-0987(02)00251-8.
2. Loftsson, T., Jarho, P., Másson, M., Järvinen, T.: Cyclodextrins in drug delivery. Expert Opin. Drug Deliv. 2, 335-351 (2005). doi:10.1517/17425247.2.1.335.
3. Higuchi, T., Connors, K.A.: Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4, 117-212 (1965).
4. Pouton, C.W.: Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur. J. Pharm. Sci. 29, 278-287 (2006). doi:10.1016/j.ejps.2006.04.016.
5. Bhattachar, S.N., Deschenes, L.A., Wesley, J.A.: Solubility: it's not just for physical chemists. Drug Discov. Today 11, 1012-1018 (2006). doi:10.1016/j.drudis.2006.09.002.
6. Hörter, D., Dressman, J.B.: Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46, 75-87 (2001). doi:10.1016/S0169-409X(00)00130-7.
7. Dressman, J.B., Amidon, G.L., Reppas, C., Shah, V.P.: Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 15, 11-22 (1998). doi:10.1023/A:1011984216775.
8. Zimmermann, T., Yeates, R.A., Laufen, H., Pfaff, G., Wildfeuer, A.: Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur. J. Clin. Pharmacol. 46, 147-150 (1994). doi:10.1007/BF00199879.
9. Dashevsky, A., Kolter, K., Bodmeier, R.: pH-independent release of a basic drug from pellets coated with the extended release polymer dispersion Kollicoatw SR 30 D and the enteric polymer dispersion Kollicoatw MAE 30 DP. Eur. J. Pharm. Biopharm. 58, 45-49 (2004). doi:10.1016/j.ejpb.2004.03.013.
10. Estelle, F., Simons, R.: Comparative pharmacology of H1 antihistamines: clinical relevance. Am. J. Med. 113(9), 38-46 (2002).
11. Khan, M.Z., Raušl, D., Zanoški, R., Zidar, S., Mikulčić, J.H., Krizmanić, L., Eškinja, M., Mildner, B., Knežević, Z.: Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. Biol. Pharm. Bull. 27(10), 1630-1635 (2004). doi:10.1248/bpb.27.1630.
12. Omar, L., El-Barghouthi, M.I., Masoud, N.A., Abdoh, A.A., Al Omari, M.M., Zughul, M.B., Badwan, A.A.: Inclusion complexation of loratadine with natural and modified cyclodextrins: phase solubility and thermodynamic studies. J. Solution Chem. 36, 605-616 (2007). doi:10.1007/s10953-007-9136-3.
13. 1-antihistaminic agents in relation to their central sedative side-effects. Eur. J. Pharm. Sci. 2, 373-384 (1994). doi:10.1016/0928-0987(94)00065-4.
14. Moffat, A.C., Osselton, M.D., Widdop, B.: Clarke's Analysis of Drugs and Poisons, 3rd ed. edn. Pharmaceutical Press, London (2004).
15. a values of basic new drug substances by CE. J. Pharm. Biomed. Anal. 26, 427-434 (2001). doi:10.1016/S0731-7085(01)00423-X.
16. Peterson, M.L., Hickey, M.B., Zaworotko, M.J., Almarsson, Ö.: Expanding the scope of crystal form evaluation in pharmaceutical science. J. Pharm. Pharm. Sci. 9, 317-326 (2006).
17. Carrier, R.L., Miller, L.A., Ahmed, I.: The utility of cyclodextrins for enhancing oral bioavailability. J. Control. Release 123, 78-99 (2007). doi:10.1016/j.jconrel.2007.07.018.
18. Badr-Eldin, S.M., Elkheshen, S.A., Ghorab, M.M.: Inclusion complexes of tadalafil with natural and chemically modified β-cyclodextrins. I: preparation and in vitro evaluation. Eur. J. Pharm. Biopharm. 70, 819-827 (2008). doi:10.1016/j.ejpb.2008.06.024.
19. Kata, M., Ambrus, R., Aigner, Z.: Preparation and investigation of inclusion complexes containing nifluminic acid and cyclodextrins. J. Incl. Phenom. 44, 123-126 (2002). doi:10.1023/A:1023074025175.
20. Hassan, H.B., Kata, M., Ero{double acute}s, I., Aigner, Z.: Preparation and investigation of inclusion complexes containing gemfibrozil and DIMEB. J. Incl. Phenom. 50, 219-225 (2004). doi:10.1007/s10847-004-3124-7.
21. Amidon, G.L., Lennernas, H., Shah, V.P., Crison, J.R.: A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413-420 (1995). doi:10.1023/A:1016212804288.
22. Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3-26 (2001). doi:10.1016/S0169-409X(00)00129-0.
23. Marttin, E., Verhoef, J.C., Merkus, F.W.: Efficacy, safety and mechanism of cyclodextrins as absorption enhancers in nasal delivery of peptide and protein drugs. J. Drug Target. 6, 17-36 (1998).
24. Loftsson, T., Brewster, M.E., Másson, M.: Role of cyclodextrins in improving oral drug delivery. Am. J. Drug Deliv. 2, 261-275 (2004). doi:10.2165/00137696-200402040-00006.
25. Desiraju, G.R.: Crystal and co-crystal. Cryst. Eng. Commun. 5, 466-467 (2003). doi:10.1039/b313552g.